Jin Piao1, John T Lafin2, Cinzia G Scarpini3, Michelle M Nuño1, Isabella Syring4, Klaus-Peter Dieckmann5, Gazanfer Belge6, Jörg Ellinger4, James F Amatruda7, Aditya Bagrodia2, Nicholas Coleman8, Mark D Krailo1, A Lindsay Frazier9, Matthew J Murray10. 1. Department of Preventive Medicine, University of Southern California, Los Angeles, CA. 2. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. 3. Department of Pathology, University of Cambridge, Cambridge, UK. 4. Department of Urology, University of Bonn, Germany. 5. Department of Urology, Asklepios Klinik Altona, Hamburg, Germany. 6. Faculty of Biology and Chemistry, University of Bremen, Bremen, Germany. 7. Cancer and Blood Disease Institute, Children's Hospital Los Angeles; and Keck School of Medicine University of Southern California, Los Angeles, CA. 8. Department of Pathology, University of Cambridge, Cambridge, UK; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 9. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA. 10. Department of Pathology, University of Cambridge, Cambridge, UK; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: mjm16@cam.ac.uk.
Abstract
BACKGROUND: Circulating microRNAs have clear potential for improving malignant germ-cell-tumor (MGCT) diagnosis. Here, we address the central issue of whether measurement of a single microRNA is sufficient for detecting testicular MGCTs, or whether there is added benefit in quantifying other members of the 4-microRNA panel previously identified (miR-371a-3p/miR-372-3p/miR-373-3p and miR-367-3p). PATIENTS AND METHODS: We performed a pooled analysis of available published raw data where all 4 panel miRNAs had been assessed using pre-amplification PCR technology (4 studies; total 329 patients). Two studies using identical methodology (and identical normalization using endogenous miR-30b-5p) were used in the discovery phase (n = 51 patients: 17 MGCT, 34 controls). The 2 other studies (n = 278 patients: 140 MGCT, 138 controls), which assessed the same test panel but with different normalization approaches (endogenous miR-93-5p, exogenous cel-miR-39-3p), were used for the validation phase. We derived sensitivity, specificity, positive- and negative-predictive-values (PPV/NPV) for the detection thresholds that maximised the Youden Index (YI). RESULTS: In the discovery-phase, the YI was 0.97 for miR-371a-3p (sensitivity = 1, specificity = 0.97), 0.71 (miR-367-3p), 0.68 (miR-372-3p), and 0.50 (miR-373-3p). These findings were confirmed in the validation-phase, with YI of 0.75 for miR-371a-3p (sensitivity = 0.90, specificity 0.85), 0.55 (miR-367-3p), 0.47 (miR-372-3p), and 0.51 (miR-373-3p). Importantly, no combination of markers added additional diagnostic benefit to miR-371a-3p alone, in either the discovery or the validation phase. CONCLUSION: Quantifying circulating miR-371a-3p alone is sufficient for testicular MGCT diagnosis. PCR measurement of this single miRNA marker will be more cost-effective and easier to interpret, facilitating future incorporation into routine clinical practice.
BACKGROUND: Circulating microRNAs have clear potential for improving malignant germ-cell-tumor (MGCT) diagnosis. Here, we address the central issue of whether measurement of a single microRNA is sufficient for detecting testicular MGCTs, or whether there is added benefit in quantifying other members of the 4-microRNA panel previously identified (miR-371a-3p/miR-372-3p/miR-373-3p and miR-367-3p). PATIENTS AND METHODS: We performed a pooled analysis of available published raw data where all 4 panel miRNAs had been assessed using pre-amplification PCR technology (4 studies; total 329 patients). Two studies using identical methodology (and identical normalization using endogenous miR-30b-5p) were used in the discovery phase (n = 51 patients: 17 MGCT, 34 controls). The 2 other studies (n = 278 patients: 140 MGCT, 138 controls), which assessed the same test panel but with different normalization approaches (endogenous miR-93-5p, exogenous cel-miR-39-3p), were used for the validation phase. We derived sensitivity, specificity, positive- and negative-predictive-values (PPV/NPV) for the detection thresholds that maximised the Youden Index (YI). RESULTS: In the discovery-phase, the YI was 0.97 for miR-371a-3p (sensitivity = 1, specificity = 0.97), 0.71 (miR-367-3p), 0.68 (miR-372-3p), and 0.50 (miR-373-3p). These findings were confirmed in the validation-phase, with YI of 0.75 for miR-371a-3p (sensitivity = 0.90, specificity 0.85), 0.55 (miR-367-3p), 0.47 (miR-372-3p), and 0.51 (miR-373-3p). Importantly, no combination of markers added additional diagnostic benefit to miR-371a-3p alone, in either the discovery or the validation phase. CONCLUSION: Quantifying circulating miR-371a-3p alone is sufficient for testicular MGCT diagnosis. PCR measurement of this single miRNA marker will be more cost-effective and easier to interpret, facilitating future incorporation into routine clinical practice.
Authors: Roger D Palmer; Matthew J Murray; Harpreet K Saini; Stijn van Dongen; Cei Abreu-Goodger; Balaji Muralidhar; Mark R Pett; Claire M Thornton; James C Nicholson; Anton J Enright; Nicholas Coleman Journal: Cancer Res Date: 2010-03-23 Impact factor: 12.701
Authors: Matthew J Murray; David J Halsall; C Elizabeth Hook; Denise M Williams; James C Nicholson; Nicholas Coleman Journal: Am J Clin Pathol Date: 2011-01 Impact factor: 2.493
Authors: Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2008-07-28 Impact factor: 11.205
Authors: Ad J M Gillis; Martin A Rijlaarsdam; Ronak Eini; Lambert C J Dorssers; Katharina Biermann; Matthew J Murray; James C Nicholson; Nicholas Coleman; Klaus-Peter Dieckmann; Gazanfer Belge; Jörn Bullerdiek; Tom Xu; Nathalie Bernard; Leendert H J Looijenga Journal: Mol Oncol Date: 2013-08-20 Impact factor: 6.603
Authors: Matthew J Murray; Emma Bell; Katie L Raby; Martin A Rijlaarsdam; Ad J M Gillis; Leendert H J Looijenga; Helen Brown; Benoit Destenaves; James C Nicholson; Nicholas Coleman Journal: Br J Cancer Date: 2015-12-15 Impact factor: 7.640
Authors: Stefan Schönberger; Mahsa Mir Mohseni; Jörg Ellinger; Giao Vu Quynh Tran; Martina Becker; Alexander Claviez; Carl-Friedrich Classen; Barbara Hermes; Pablo Hernáiz Driever; Norbert Jorch; Melchior Lauten; Marcus Mehlitz; Niklas Schäfer; Johanna Scheer-Preiss; Dominik T Schneider; Anja Troeger; Gabriele Calaminus; Dagmar Dilloo Journal: J Cancer Res Clin Oncol Date: 2022-02-16 Impact factor: 4.553
Authors: Adriana Fonseca; João Lobo; Florette K Hazard; Joanna Gell; Peter K Nicholls; Robert S Weiss; Lindsay Klosterkemper; Samuel L Volchenboum; James C Nicholson; A Lindsay Frazier; James F Amatruda; Aditya Bagrodia; Michelle Lockley; Matthew J Murray Journal: Br J Cancer Date: 2022-10-13 Impact factor: 9.075